Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Julphar
Express Scripts
Mallinckrodt
Argus Health
Dow
Daiichi Sankyo
Johnson and Johnson
Cipla
Deloitte

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,342,482

« Back to Dashboard

Which drugs does patent 6,342,482 protect, and when does it expire?

Patent 6,342,482 protects NATROBA and is included in one NDA.

This patent has thirty-six patent family members in twenty-eight countries.
Summary for Patent: 6,342,482
Title: Formulations for controlling human lice
Abstract:Safer pediculicidal formulations comprising a spinosyn, or a physiologically acceptable derivative or salt thereof, and a physiologically acceptable carrier, and methods of controlling lice infestations in a human with these formulations are provided.
Inventor(s): Snyder; Daniel Earl (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:09/543,441
Patent Claim Types:
see list of patent claims
Formulation; Compound;

Drugs Protected by US Patent 6,342,482

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Parapro Llc NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,342,482

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,063,771 Formulations for controlling human lice ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,342,482

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 326212 ➤ Try a Free Trial
Australia 4700499 ➤ Try a Free Trial
Australia 750046 ➤ Try a Free Trial
Brazil 9911795 ➤ Try a Free Trial
Canada 2337789 ➤ Try a Free Trial
China 1129430 ➤ Try a Free Trial
China 1314812 ➤ Try a Free Trial
Czech Republic 20004865 ➤ Try a Free Trial
Czech Republic 296136 ➤ Try a Free Trial
Germany 69931309 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Fish and Richardson
Cerilliant
Baxter
Chubb
Cipla
Fuji
Teva
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot